NASDAQ:BDTX Black Diamond Therapeutics (BDTX) Stock Price, News & Analysis $1.44 -0.09 (-5.88%) Closing price 11/17/2026 04:00 PM EasternExtended Trading$1.46 +0.02 (+1.04%) As of 11/17/2026 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About Black Diamond Therapeutics Stock (NASDAQ:BDTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BDTX alerts:Sign Up Key Stats Today's Range$1.39▼$1.5350-Day Range$1.44▼$2.1052-Week Range$1.39▼$4.06Volume645,968 shsAverage Volume913,851 shsMarket Capitalization$82.76 millionP/E RatioN/ADividend YieldN/APrice Target$11.00Consensus RatingModerate Buy Company Overview Black Diamond Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing precision medicines for people with genetically defined cancers. The company uses its discovery platform to identify cancer-causing mutations and develop small-molecule therapies designed to target them. Its pipeline has included BDTX-1535, an investigational inhibitor designed to target certain EGFR alterations in cancers such as non-small cell lung cancer. The company’s candidates are in clinical development; it does not have an approved commercial product. Founded in 2014 and headquartered in Cambridge, Massachusetts, Black Diamond Therapeutics conducts research and clinical development with the goal of addressing cancer mutations that may not be served by existing treatments.AI Generated. May Contain Errors. Read More Black Diamond Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks46th Percentile Overall ScoreBDTX MarketRank™: 2.278295605855 of 5 starsBlack Diamond Therapeutics scored higher than 46% of companies evaluated by MarketBeat, and ranked 540th out of 859 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingModerate Buy Consensus RatingBlack Diamond Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on no strong buy ratings, 7 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialBlack Diamond Therapeutics has a consensus price target of $11.00, representing about 663.9% upside from its current price of $1.44.Amount of Analyst CoverageBlack Diamond Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Black Diamond Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Black Diamond Therapeutics are expected to decrease in the coming year, from ($0.72) to ($1.01) per share.Price to Book Value per Share RatioBlack Diamond Therapeutics has a P/B Ratio of 0.94. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.80% of the float of Black Diamond Therapeutics has been sold short.Short Interest Ratio / Days to CoverBlack Diamond Therapeutics has a short interest ratio ("days to cover") of 4.87.Change versus previous monthShort interest in Black Diamond Therapeutics has recently increased by 2.07%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBlack Diamond Therapeutics does not currently pay a dividend.Dividend GrowthBlack Diamond Therapeutics does not have a long track record of dividend growth. News and Social Media2.3 / 5News SentimentN/A News SentimentBlack Diamond Therapeutics has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.Search InterestOnly 1 people have searched for BDTX on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat Follows3 people have added Black Diamond Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership1.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Black Diamond Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders9.29% of the stock of Black Diamond Therapeutics is held by insiders.Percentage Held by Institutions95.47% of the stock of Black Diamond Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Black Diamond Therapeutics' insider trading history. Receive BDTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Black Diamond Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BDTX Stock News HeadlinesBlack Diamond Posts Strong Silevertinib Data; FDA Supports Phase 3 Path; Shares RiseNovember 10, 2026 | rttnews.comBlack Diamond Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 10, 2026 | marketscreener.comMDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out. | Weiss Ratings (Ad)Black Diamond Therapeutics Announces Positive Updated Silevertinib Phase 2 Results, FDA Feedback Supporting a Clear Path to Potential Registration in 1L EGFR-NCM NSCLC, and ...November 10, 2026 | finance.yahoo.comBlack Diamond Therapeutics Announces Positive Updated Silevertinib Phase 2 Results, FDA Feedback Supporting a Clear Path to Potential Registration in 1L EGFR-NCM NSCLC, and Provides Corporate UpdateNovember 10, 2026 | globenewswire.comBlack Diamond Therapeutics to Host Webcast Highlighting Updated Silevertinib Phase 2 Data and FDA Feedback Supporting a Clear Phase 3 Path to Potential Accelerated Approval in ...November 9, 2026 | finance.yahoo.comBlack Diamond Therapeutics: Delay In Trial Results Leads To A Downgrade, But It's Still A BuyNovember 3, 2026 | seekingalpha.comBlack Diamond Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment ConferenceSeptember 2, 2026 | globenewswire.comSee More Headlines BDTX Stock Analysis - Frequently Asked Questions How have BDTX shares performed this year? Black Diamond Therapeutics' stock was trading at $2.43 at the start of the year. Since then, BDTX stock has decreased by 40.7% and is now trading at $1.44. How were Black Diamond Therapeutics' earnings last quarter? Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) announced its quarterly earnings data on Tuesday, November, 10th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.09) by $0.08. When did Black Diamond Therapeutics IPO? Black Diamond Therapeutics (BDTX) raised $180 million in an initial public offering (IPO) on Thursday, January 30th 2020. The company issued 10,586,316 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Jefferies and Cowen acted as the underwriters for the IPO and Canaccord Genuity was co-manager. Who are Black Diamond Therapeutics' major shareholders? Black Diamond Therapeutics' top institutional shareholders include Marshall Wace LLP (2.05%), State Street Corp (1.64%), Goldman Sachs Group Inc. (1.20%) and AWM Investment Company Inc. (1.13%). View institutional ownership trends. How do I buy shares of Black Diamond Therapeutics? Shares of BDTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Black Diamond Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Black Diamond Therapeutics investors own include Cabaletta Bio (CABA), NVIDIA (NVDA), Precision BioSciences (DTIL), Editas Medicine (EDIT), Gossamer Bio (GOSS), Kaleido Biosciences (KLDO) and Micron Technology (MU). Company Calendar Last Earnings11/10/2026Today11/17/2026Jefferies Global Healthcare Conference11/19/20269th Annual Evercore ISI HealthCONx Conference12/01/202638th Annual Healthcare Conference12/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 8 days, BDTX's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:BDTX CIK1701541 Webwww.blackdiamondtherapeutics.com Phone(617) 417-5868FaxN/AEmployees21Year Founded2017Price Target and Rating Average Price Target for Black Diamond Therapeutics$11.00 High Price Target$14.00 Low Price Target$8.00 Potential Upside/Downside+663.9%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($0.77) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$22.37 million Net MarginsN/A Pretax MarginN/A Return on Equity-36.66% Return on Assets-28.44% Debt Debt-to-Equity RatioN/A Current Ratio6.92 Quick Ratio6.92 Sales & Book Value Annual Sales$70 million Price / Sales1.18 Cash Flow$0.50 per share Price / Cash Flow2.90 Book Value$1.53 per share Price / Book0.94Miscellaneous Outstanding Shares57,470,000Free Float52,129,000Market Cap$82.76 million OptionableOptionable Beta3.48 Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NASDAQ:BDTX) was last updated on 11/17/2026 by MarketBeat.com Staff. From Our PartnersYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredAmerica's Biggest Bank… Down?About 4,800 Chase customers reported problems in just 15 minutes on Monday. Many couldn't log in or move money...Decentralized Masters | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | Sponsored432 miles southeast of Washington, DC…Spruce Pine, North Carolina, a town of just over 2,000 people, has supplied a material to every major chip mak...Wall Street Watchdogs | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Black Diamond Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Black Diamond Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.